London
· Delayed Price · Currency is GBP · Price in USD Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of GBP 907.69 million. The enterprise value is 942.77 million.
| Market Cap | 907.69M |
| Enterprise Value | 942.77M |
Important Dates
The next estimated earnings date is Tuesday, February 25, 2025.
| Earnings Date | Feb 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +9.79% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 83.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 9.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.89 |
| EV / Sales | 1.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.25 |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.90 |
| Quick Ratio | 1.46 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.50 |
| Interest Coverage | -31.80 |
Financial Efficiency
Return on equity (ROE) is -16.39% and return on invested capital (ROIC) is -6.78%.
| Return on Equity (ROE) | -16.39% |
| Return on Assets (ROA) | -5.35% |
| Return on Capital (ROIC) | -6.78% |
| Revenue Per Employee | 227,588 |
| Profits Per Employee | -32,055 |
| Employee Count | 2,700 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 9.91 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.29% in the last 52 weeks. The beta is 1.78, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.78 |
| 52-Week Price Change | -38.29% |
| 50-Day Moving Average | 14.97 |
| 200-Day Moving Average | 21.55 |
| Relative Strength Index (RSI) | 34.50 |
| Average Volume (20 Days) | 456 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.79 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of GBP 614.49 million and -86.55 million in losses. Loss per share was -0.97.
| Revenue | 614.49M |
| Gross Profit | 424.90M |
| Operating Income | -71.18M |
| Pretax Income | -87.07M |
| Net Income | -86.55M |
| EBITDA | -25.29M |
| EBIT | -71.18M |
| Loss Per Share | -0.97 |
Balance Sheet
The company has 74.54 million in cash and 106.77 million in debt, giving a net cash position of -32.23 million.
| Cash & Cash Equivalents | 74.54M |
| Total Debt | 106.77M |
| Net Cash | -32.23M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 545.92M |
| Book Value Per Share | 6.00 |
| Working Capital | 103.63M |
Cash Flow
In the last 12 months, operating cash flow was -52.23 million and capital expenditures -18.95 million, giving a free cash flow of -71.18 million.
| Operating Cash Flow | -52.23M |
| Capital Expenditures | -18.95M |
| Free Cash Flow | -71.18M |
| FCF Per Share | n/a |
Margins
Gross margin is 69.15%, with operating and profit margins of -11.58% and -14.08%.
| Gross Margin | 69.15% |
| Operating Margin | -11.58% |
| Pretax Margin | -14.17% |
| Profit Margin | -14.08% |
| EBITDA Margin | -4.12% |
| EBIT Margin | -11.58% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.79% |
| Shareholder Yield | -9.79% |
| Earnings Yield | -9.53% |
| FCF Yield | -7.84% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Myriad Genetics has an Altman Z-Score of 3.07.
| Altman Z-Score | 3.07 |
| Piotroski F-Score | n/a |